Uncategorized
Domain Associates-backed OcuNexus Therapeutics Making Significant Progress with Inflammasome Inhibition Program in Ophthalmic Disease with Key Addition to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--OcuNexus Therapeutics, a clinical stage biotechnology company developing a first-in-class orally administered treatment for the dry form of age-related macular degeneration and diabetic retinopathy, today announced that it has strengthened its board of directors with the addition of Mr. Rajiv Shukla, who has deep experience in the investment and commercial aspects of the pharmaceutical industry. “OcuNexus technology targets an upstream protein to inhibit the patholog